Home/Pipeline/Katana Thrombectomy System

Katana Thrombectomy System

Pulmonary Embolism (PE)

Pivotal TrialActive

Key Facts

Indication
Pulmonary Embolism (PE)
Phase
Pivotal Trial
Status
Active
Company

About Akura Medical

Akura Medical is a clinical-stage medical device company targeting the large and underserved venous thromboembolism (VTE) market, specifically pulmonary embolism (PE). Its core technology is the Katana Thrombectomy System, which combines an intelligent catheter, HydroBlade jet technology, and a Sentinel console for real-time procedural insights to address limitations of existing treatments. Backed by Shifamed's innovation hub and having recently closed a $53M Series C round, the company is actively enrolling patients in a U.S. pivotal trial for PE, positioning it for potential future commercialization. Akura operates as a private, pre-revenue entity advancing a single, integrated platform through clinical development.

View full company profile

Other Pulmonary Embolism (PE) Drugs

DrugCompanyPhase
Platform ExtensionRetriever MedicalPre-clinical/Concept
FlowTriever SystemInari MedicalCommercial / PMA Supplement